WCTF.org Transplant News

PHILADELPHIA, April 30 /PRNewswire-USNewswire/ -- Hahnemann University Hospital, St. Christopher's Hospital for Children and Independence Blue Cross (IBC) announced today that they have reached agreement in principle on terms of new contracts. They have extended their current agreements while they define terms for new multi-year contracts. Hahnemann and St. Christopher's are both part of Tenet Healthcare Corporation's (NYSE:THC) national network of hospitals. The parties will continue to work together to finalize details of the new contracts with a targeted effective date of July 1, 2008.

Members of IBC will continue to have access to health care services offered at the two hospitals, their outpatient centers and employed physician practices. The parties have been working to reach new agreements in advance of the current contract termination, which was to have occurred on April 30.

"We are pleased to reach an agreement that avoids a potentially disruptive contract termination for our patients," said Michael P. Halter, chief executive officer of Hahnemann University Hospital. "This extension of our agreement means that we can continue providing care to our patients who are covered by Independence Blue Cross."

Bernadette Mangan, chief executive officer of St. Christopher's Hospital for Children, said, "We welcome the opportunity to continue working with Independence Blue Cross to provide quality care for their members."

"We value our longstanding relationship with Hahnemann and St. Christopher's Hospitals and are pleased that we have achieved an understanding as the basis for a new agreement," said I. Steven Udvarhelyi, chief medical officer and senior vice president. "More importantly, our members will continue to receive quality care from these institutions."

About Independence Blue Cross

Independence Blue Cross is a leading health insurer in Southeastern Pennsylvania. IBC and its affiliates provide coverage to nearly 3.4 million people. For 70 years, Independence Blue Cross has offered high-quality health care coverage tailored to meet the changing needs of members, employers, and health care professionals. Independence Blue Cross is an independent licensee of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. To learn more about Independence Blue Cross, visit www.ibx.com.

About Hahnemann University Hospital

Hahnemann University Hospital is a 540-bed academic medical center at Broad and Vine Streets in Philadelphia, Pa. The hospital is a tertiary care institution that specializes in cardiac services, heart failure and transplantation, OB/GYN, orthopedics, medical, surgical and radiation oncology, bone marrow transplantation, renal dialysis and kidney/pancreas/liver transplantation. Hahnemann has been named by U.S. News and World Report as one of the nation's top fifty hospitals for heart care and is also recognized by the American Heart Association as a leader in coronary artery disease and heart failure treatments. The hospital performed one of the city's first kidney transplants in 1963 and one of the first bone marrow transplants in 1976. Hahnemann became Philadelphia's first Level I Regional Resource Trauma Center for adults in 1986, and since then has been served by MidAtlantic MedEvac, an aeromedical transport program for critically ill patients. Hahnemann is proud to be the first hospital in Philadelphia to join with The Wellness Community of Philadelphia to offer onsite support and education services to cancer patients and their families. Hahnemann is fully accredited by the Joint Commission on the Accreditation of Healthcare Organizations, the nation's oldest and largest hospital accreditation agency. An affiliate of Drexel University College of Medicine, Hahnemann University Hospital is part of Tenet Pennsylvania, which also includes St. Christopher's Hospital for Children. To learn more about Hahnemann, visit www.hahnemannhospital.com.

About St. Christopher's Hospital for Children

St. Christopher's Hospital for Children is a 170-bed pediatric hospital located at 3601 A Street in Philadelphia, PA that has an academic affiliation with Drexel University College of Medicine and the Temple University School of Medicine. The hospital provides a wide range of pediatric medical and surgical specialties. With a medical staff of more than 270 pediatric specialists, St. Christopher's is a Level I Pediatric Trauma Center and provides programs such as kidney transplantation, cancer treatment, burn and wound care, minimally invasive surgery, and open heart surgery for the children of the greater Philadelphia area and from around the world. The hospital is fully accredited by the Joint Commission, the nation's oldest and largest hospital accreditation agency. St. Christopher's Hospital for Children is part of Tenet Healthcare Corporation's Hospitals in the Philadelphia market. To learn more about St. Christopher's Hospital for Children, visit www.stchristophershospital.com.

First Call Analyst:
FCMN Contact:

http://www.ibx.com

http://www.stchristophershospital.com/

Source: Hahnemann University Hospital

CONTACT: Coleen Cannon of Hahnemann University Hospital, Office:
+1-215-762-7235, Cell: +1-215-439-0066; or Karen Godlewski of Independence
Blue Cross, Office: +1-215-241-3113, Cell: +1-609-413-6803

Web Site:

http://www.hahnemannhospital.com/

-------
Profile: Transplant News

Thousands Saved and Healed by Registered Organ and Tissue Donors

SACRAMENTO, Calif., April 30 /PRNewswire-USNewswire/ -- Families of organ and tissue donors joined organ transplant recipients at the State Capitol on April 30 to formally thank lawmakers, the Department of Motor Vehicles (DMV) and the three million Californians who have pledged to save and heal lives by signing up on the state-authorized Donate Life California Organ & Tissue Donor Registry.

Governor Arnold Schwarzenegger, along with Assemblywoman Sharon Runner (R - Lancaster) joined fellow legislators, DMV representatives, and allied health professionals to officially commemorate April's DMV/Donate Life California Month.

"The benefits of organ and tissue donation are simply staggering," Governor Schwarzenegger said. "I am proud of the 3 million Californians who have signed up to be organ and tissue donors. Each person who becomes a donor can save the lives of eight people and dramatically improve the lives of 50 people. It truly is the gift of life."

The number of individuals who wait for a life saving transplant continues to increase on a daily basis. California has the highest proportion of people on the national organ transplant waiting list, with about 20 percent of the nearly 100,000 candidates awaiting a life-saving transplant.

"Californians have an extraordinary opportunity to help save lives and ensure their decision to do so is honored," Runner said. Runner authored Assembly Concurrent Resolution 125, a resolution recognizing April as DMV/Donate Life California Month to encourage Californians to sign up with the Donate Life California Registry.

"Each of us has the power to save up to eight lives as an organ donor and heal up to 50 others as a tissue donor by restoring sight, mobility, and healing burns," Runner added. "I strongly encourage every Californian to sign up with the registry."

Altogether, registered organ and tissue donors saved or healed more than 3,000 lives in 2007. Anyone can sign up on the Donate Life California Registry, and unlike blood donation, there are few automatic rule-outs.

"We are pleased that in the last year, the Donate Life California Registry has shown its value as a tool to save and heal lives," Bryan Stewart, President of Donate Life California, said. "With one million designated donors signing up every eight months, the life-saving impact of the registry is on an upward trajectory."

The success of the Donate Life California Registry owes much to its partnership with the Department of Motor Vehicles. "Today we celebrate three million Californians who have signed up to become organ and tissue donors," DMV Director George Valverde said. "Those 'pink dots' are more than mere symbols; they have taken on the power of advanced directives for organ and tissue donation for any California motorist who proudly chooses to display them."

The vast majority of the registry's three million designated donors have signed up since the DMV began enrolling designated donors in July 2006. Due to the five year license renewal cycle, two-thirds of California drivers have not yet had the opportunity to check 'yes' when they renew their license, and state lawmakers urge individuals to do so.

In all cases in which an eligible donor has not registered with Donate Life California, the donation decision falls on families, who consent to donation in about 60% of cases. When families are unsure of what their loved one wanted, after sometimes anguishing deliberation, they often decline to donate. Thus, documenting one's decision on the registry is a gift both to one's family and to potential recipients.

"The registry's core promise - to save lives by ensuring individuals' wishes to donate are honored - is accomplishing its life-saving mission," Stewart said.

Donate Life California is a nonprofit, state-authorized organ and tissue donor registry, administered by California's four nonprofit, federally designated organ procurement organizations, each responsible for facilitating the donation process in the state: California Transplant Donor Network, Golden State Donor Services, Lifesharing and OneLegacy.

For more information, please visit http://www.dmv.ca.gov/about/donateLife/donateLife.htm, http://www.donatelifecalifornia.org/ or in Spanish at http://www.donevidacalifornia.org/.

(Editor's note: Donate Life California statistics follows)

Donate Life California Registry Enrollment, 2005-2007

Quarter Quarterly Cumulative Total
Enrollment
2Q05 77,940 77,940
3Q05 63,162 141,102
4Q05 51,879 192,981
1Q06 58,446 251,427
2Q06 45,918 297,345
3Q06 362,799 660,144
4Q06 288,163 948,307
1Q07 304,324 1,252,631
2Q07 386,456 1,639,087
3Q07 442,798 2,081,885
4Q07 388,194 2,470,079
1Q08 399,417 2,869,496
Source: Donate Life California

First Call Analyst:
FCMN Contact:

http://www.donateLIFEcalifornia.org

Source: Donate Life California

CONTACT: Kayla Garcia of the Office of Assemblywoman Sharon Runner,
Office: +1-916-319-2036, Cell: +1-661-993-7070; or Jan Mendoza of the DMV,
Office: +1-916-657-6826; or Bryan Stewart, President of Donate Life
California, Office: +1-213-229-5650, Cell: +1-213-400-8304, or Miryam Mora,
Executive Director of Donate Life California, Office: +1-916-473-0875

Web Site:

http://www.dmv.ca.gov/

-------
Profile: Transplant News

Idiopathic pulmonary fibrosis (IPF) patients learn from specialists, seek answers about incurable disease

BOSTON, April 30 /PRNewswire-USNewswire/ -- The following announcement was released by The Coalition for Pulmonary Fibrosis:

WHAT: "Living with IPF" Free Educational Seminar for Patients and Their Families

Beth Israel Deaconess Medical Center (BIDMC) in partnership with The Coalition for Pulmonary Fibrosis (CPF), is hosting a free seminar for patients and families living with idiopathic pulmonary fibrosis (IPF), a fatal disease that affects 128,000 Americans and claims as many lives each year as breast cancer (40,000). Incidence and prevalence have grown more than 150 percent in just five years.

The seminar will address:
-- IPF diagnostic strategies
-- current standards of care and research
-- lung transplantation
-- oxygen management
-- pulmonary rehabilitation
-- life management issues
-- resources and support services

When:
Saturday, May 3, 2008
11:00 a.m. - 12 noon Registration and Lunch
12:00 noon - 4:20 p.m. Seminar
Complimentary lunch included

Where:
BIDMC West Campus Kennedy Building Auditorium
One Autumn Street (corner of Longwood Avenue and the Riverway)

Parking is available at the Pilgrim Road Garage on the West Campus for $10. Entrance is located off Crossover Street, which can be reached by either Pilgrim Road or Autumn Street.

**DO NOT use the garage adjacent to Bruegger's Bagel off Longwood Avenue.

WHO:

An interview opportunity with IPF experts and patients who know what it's like living with this disease, including:

-- IPF patients who live in the Boston area
-- The seminar will feature nationally recognized experts in the
treatment and study of IPF, including Joe Zibrak, MD, Peter LaCamera,
MD, David Roberts, MD, and Sidhu Gangadharan, all from BIDMC and
Hilary Goldberg, MD of Brigham and Women's Hospital

BACKGROUND:

IPF is a progressive and often fatal lung disease characterized by scarring of the lung tissue, eventually robbing patients of their ability to breathe. About 40,000 people will die from IPF this year, the same number as from breast cancer. An estimated 128,000 people in the United States have IPF, and 48,000 new cases are diagnosed each year. There is currently no FDA-approved treatment for IPF, no cure, and two-thirds of patients die within five years of diagnosis.

A recent study conducted by the Coalition for Pulmonary Fibrosis* found IPF awareness is alarmingly low -- less than one-third of Americans polled had heard of IPF, while 88 percent were aware of cystic fibrosis, and 85 percent knew of ALS, or Lou Gehrig's Disease. IPF is several times more common than cystic fibrosis and ALS, yet it receives a fraction of the research funding.

* Respiratory Medicine: Volume 101, Issue 6, June 2007, Pages 1350-1354 Patient experiences with pulmonary fibrosis Collard, Tino, Noble, Shreve, Michaels, Carlson, Schwarz. (http://www.coalitionforpf.org/ofs/pdf/BRQRespiratoryMedicinePaper.pdf)

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis, while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. For more information, visit www.coalitionforpf.org.

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and consistently ranks among the top four in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.harvard.edu.

CONTACTS:
Teresa Barnes, CPF, 1-888-222-8541, x. 702, tbarnes@coalitionforpf.org,
cell: 303-521-4080
Jerry Berger, Beth Israel Deaconess Medical Center, 617-667-7308,
jberger@bidmc.harvard.edu
First Call Analyst:
FCMN Contact:

Source: Coalition for Pulmonary Fibrosis

CONTACT: Teresa Barnes of The Coalition for Pulmonary Fibrosis,
+1-888-222-8541 ext 702, cell: +1-303-521-4080, tbarnes@coalitionforpf.org; or
Jerry Berger of Beth Israel Deaconess Medical Center, +1-617-667-7308,
jberger@bidmc.harvard.edu

Web Site:

http://www.coalitionforpf.org/

-------
Profile: Transplant News

National Walk @ Lunch Day(SM) encourages healthier lifestyles

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- Blue Cross and Blue Shield companies nationwide are working with employers of all sizes to get their workers to take steps toward healthier lifestyles. Citing the tremendous cost that inactive lifestyles and preventable health conditions have on the nation's healthcare bill, Blue Cross and Blue Shield companies are holding lunchtime walks across America as part of the second annual National Walk @ Lunch Day.

Blue Cross and Blue Shield companies are hosting the walks in all 50 states, the District of Columbia and Puerto Rico to engage employees, members and community leaders in healthy activities to promote the benefits of walking. Nationwide, thousands of walkers from companies, organizations, state and local governments are participating in this healthy initiative.

Regular, brisk walking is one of the simplest and safest forms of physical exercise and a regular walking program can help control weight, condition the heart and lungs, strengthen bones and help you take the first step to a healthier future. Regular walking also has other positive impacts on health, including decreasing the risk of a heart attack, reducing the risk of developing type 2 diabetes, helping to control weight and improving muscle tone.

"More than 60 percent of all adults in our country do not engage in the recommended amount of physical activity," said Scott P. Serota, president and CEO of the Blue Cross and Blue Shield Association (BCBSA). "This lack of regular physical exercise can lead to illness and chronic diseases down the road. National Walk @ Lunch Day is not only an opportunity for Americans to step outside and take a lunchtime walk, but it is an opportunity to join the Blue Cross and Blue Shield companies in leading a call to action for the nation to embark on a path to a healthier lifestyle."

In Washington, D.C., CareFirst BlueCross BlueShield and Blue Cross and Blue Shield Federal Employee Program employees are joining the U.S. Department of Health and Human Services (HHS) in co-hosting a National Walk @ Lunch Day event at the Hubert H. Humphrey building for federal government employees.

"Modern medical science gives every one of us the opportunity to be among the healthiest people who've ever lived," said Health and Human Services Deputy Secretary Tevi Troy. "But if you want to live a long and healthy life, you also have to eat well, avoid risky behaviors, and exercise regularly. We at HHS are encouraging people to make these smart choices, and it's great to see private companies doing this as well."

Nationwide, hundreds of companies, organizations, state and local governments are hosting or participating in National Walk @ Lunch Day events across the country such as Emerson Hospital in Concord, Massachusetts, and Kayser-Roth Corporation in Greensboro, North Carolina.

"Emerson Hospital is committed to the health and well-being of our employees," said Christine Schuster, president and CEO, Emerson Hospital. "We know our employees are busy, so walking at lunchtime is a great way to integrate exercise into our day while spending some time with co-workers outside of the office. I look forward to joining my team as we walk our way to better health."

"Our goal at Kayser-Roth Corporation is to leave a legacy of healthier employees by creating an environment that encourages healthier lifestyles," said Rae Mackall, vice president of human resources at North Carolina- based Kayser-Roth Corporation. "We are encouraging our employees to walk on April 30th for National Walk @ Lunch Day as a way to motivate our team to walk everyday."

Below are highlights of some of the National Walk @ Lunch Day activities taking place across the country:

-- In Chicago, Blue Cross and Blue Shield of Illinois and BCBSA are
hosting National Walk @ Lunch Day in Grant Park for Loop-based
employers to participate in a lunchtime walk.

-- Independence Blue Cross (IBC) will lead the charge on walking toward
better health in Philadelphia when nearly 4,000 IBC associates and
other local workforce employees walk three laps around Philadelphia
City Hall in the heart of the downtown business area. Mayor Michael
Nutter will be walking along with Dick Vermeil, former coach for the
Philadelphia Eagles, who will share personal insight on investing in
fitness for life. Actor-historian Ben Franklin will also reminisce
about Philadelphia's early days as a city for walking.

-- In addition to organizing walks at its offices across Arizona, Blue
Cross Blue Shield of Arizona is hosting a National Walk @ Lunch Day
event on the Senate lawn of the Capitol Complex in Phoenix to
congratulate winners of the State Senate health and wellness program
for Senate staffers. Activities will include a ceremonial walk around
a park adjacent to the State Capitol, led by fifth-grade students
representing the winning elementary school in the 2008 Walk On!
Challenge.

-- In Florida, Blue Cross and Blue Shield of Florida is holding more than
15 walks across the state, including in four locations in
Jacksonville, Gainesville, Miami, Ft. Lauderdale, West Palm Beach,
Orlando, Pensacola, Tampa, Sarasota, Ft. Myers and Port St. Lucie. In
addition, several Blue Cross and Blue Shield of Florida members will
hold walks for their employees including the Clay County Board of
Commissioners; Exactech, Alachua County Board of County Commissioners,
and RTI Biologics (Gainesville); The Blood Alliance (Jacksonville),
and Goodwill Industries Suncoast, Inc.

-- In Baton Rouge, Blue Cross and Blue Shield of Louisiana is hosting an
event at their Baton Rouge campus. The event will feature a Blue
Cross and Blue Shield of Louisiana employee who lost 50 pounds by
walking, as well as New Orleans Saints player Mike Karney, a spokesman
for BCBSLA's Louisiana 2 Step wellness program. The employees are
also participating in a "2-Ton Challenge," where Blue Cross and Blue
Shield of Louisiana is trying to collectively lose 2 tons of weight in
2 years.

-- Anthem Blue Cross will mobilize their more than 4,000 associates from
throughout California to participate in walks throughout the
communities where their offices are located. Then, over the next
couple of months, all associates will have the opportunity to
participate in a company wide fitness challenge to encourage Anthem
staff to get physically active and lead a healthier lifestyle.

-- Blue Cross and Blue Shield of Vermont is hosting six community walks
throughout the state in Burlington, Montpelier, Rutland, St. Johnsbury
and Bennington. Additionally, BCBSVT coordinated walks at more than
50 employee sites and, with support from the Vermont teachers'
wellness program, sponsored student/teacher walks in 37 schools.
Vermont expects at least one in every 100 Vermonters to walk on
National Walk @ Lunch Day.

-- In Columbia, South Carolina, BlueCross BlueShield of South Carolina is
hosting a walk and health fair at Columbia's Finlay Park and is
inviting everyone who works in the area as well as the general public
to participate in the walk and other festivities.

-- Anthem Blue Cross and Blue Shield in Colorado will be joined by CBS4
to walk Civic Center Park in honor of Walk @ Lunch. The walk will be
led by Mari Teitelman, a former Anthem Behavioral Health associate,
transplant survivor and winner of 5 medals in the World Transplant
Olympics, including 3 Gold Medals, and Homer Harris, aged 82, father
of Anthem's managing associate general counsel. Teitelman is training
to compete in the World Transplant Olympics again this July. "Fit and
fabulous," Harris, will talk about how exercise continues to be a
staple in his daily life. Harris not only runs and plays tennis five
days a week - he just joined Team Anthem in climbing 110 flights of
stairs for the American Lung Association's "Run the Republic" - the
event's oldest participant!

For more information, please visit www.bcbs.com/walkatlunch.

The Blue Cross and Blue Shield Association is a national federation of 39 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide healthcare coverage for more than 100 million individuals - one-in-three Americans. For more information on the Blue Cross and Blue Shield Association and its member companies, please visit www.BCBS.com.

First Call Analyst:
FCMN Contact:

Source: Blue Cross and Blue Shield Association

CONTACT: Kelly Miller of Blue Cross and Blue Shield Association,
+1-202-626-4825, kelly.miller@bcbsa.com

Web Site:

http://www.bcbs.com/walkatlunch

-------
Profile: Transplant News

WHAT: The Temple University Hospital Auxiliary will honor Dr. Kenneth
Mangan, MD, FACP, Director of the Temple Bone Marrow Transplant
(BMT) Program, with the prestigious Diamond Award for leading the
BMT Program to its 1,000th transplantation. This year's gala --
themed Run for the Roses -- marks the Auxiliary's 55th annual
"Acres of Diamonds" fundraising event. Kevin Walsh, of CN8, will
emcee the event.

Every year since 1991, the Diamond Award is presented to an
individual for his or her social responsibility to the community
and the Temple family. The "Acres of Diamonds" gala is a
culmination of the Auxiliary's annual fundraising efforts for
Temple University Hospital.

In attendance will be Dr. Ann Weaver Hart, President of Temple
University; Joseph W. "Chip" Marshall, III, President and CEO of
Temple University Health System; Maureen Mattiacci, President of
the Temple University Hospital Auxiliary; and other key Temple
administrators.

WHEN: Saturday, May 3, 2008
6:30 p.m. - 10:30 p.m.

Note to Editors: Cocktails to begin at 6:30 p.m., with dinner to
follow at 7:30 p.m. Award presentation will begin at
approximately 9:00 p.m.

WHERE: Grand Ballroom
The Westin Philadelphia
99 South 17th Street (at Liberty Place)
Philadelphia, PA 19103

Contact: Rebecca Harmon
(215) 707-8229
rebecca.harmon@tuhs.temple.edu

PRNewswire -- April 30

Source: Temple University Hospital Auxiliary

Web site:

http://www.templehealth.org/

-------
Profile: Transplant News

EXTON, Pa., April 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (NASDAQ:VPHM) reported today its financial results for the first quarter ended March 31, 2008.

Key events since December 31, 2007 include:

Development:

-- Notified sites participating in Phase 3 study of Camvia(TM) (maribavir)
in stem cell transplant patients that enrollment will be complete by
the end of May 2008;
-- Patient enrollment continued in Phase 3 study of maribavir in solid
organ transplant patients;
-- Prelaunch activities for maribavir accelerated in preparation for
planned 2009 initial NDA and MAA filing for maribavir in stem cell
transplant patients;
-- Announced in April that we have discontinued the development of HCV-796
due to the previously announced safety issue that emerged in the
ongoing Phase 2 trial in patients with hepatitis C; and
-- Efforts continued to optimize manufacturing and scale up for non-
toxigenic C. difficile (NTCD) program;

Operational:

-- Vincent J. Milano succeeded Michel de Rosen as president and chief
executive officer;
-- Daniel B. Soland appointed chief operating officer;
-- Net sales of Vancocin(R) achieved $51 million;
-- Vancocin direct sales efforts commenced; and
-- Research and development expenses increased by 171 percent over the
first quarter of 2007, primarily driven by investments in maribavir,
NTCD and increased personnel to support clinical development and
regulatory requirements;

Financial Results:

-- Operating income was $20 million;
-- Increased working capital by $25 million to $619 million;
-- Cash, cash equivalents and short-term investments grew by $15 million
to $599 million; and
-- 13th consecutive quarter of positive cash flow and profitability
achieved.

Financial Highlights

Net sales of Vancocin(R) were $50.9 million for the first quarter of 2008 as compared to $49.0 million for the first quarter of 2007.

Investment in our product pipeline and the Company continued to grow as research and development (R&D) and selling, general and administrative (SG&A) expenses were $27.8 million for the first quarter of 2008 compared to $12.5 million for the first quarter of 2007. These increases were due primarily to the costs, including the costs of increased personnel associated with our phase 3 program for maribavir, along with increased selling, general and administrative expense due to compensations costs, including share-based compensation, which resulted from increased headcount for our European operations and our Vancocin(R) sales force, as well as medical education activities and marketing efforts.

Operating income in the first quarter ended March 31, 2008 was $19.5 million compared to $32.9 million in the first quarter of 2007. Operating income in the first quarter decreased primarily due to higher R&D and SG&A costs discussed above partially offset by the higher net sales.

"The beginning of 2008 has been both a strong period of execution and growing momentum for the company," stated Vincent Milano, ViroPharma's president and chief executive officer. "Our efforts around maribavir, including the ongoing pivotal Phase 3 clinical studies, pre-launch activities, global filing strategy and launch plan development, are all proceeding towards our planned 2009 initial NDA and MAA filings. We've also had continued progress in our C. difficile franchise. The performance of Vancocin was strong, keeping us on track to generate between $210 and $235 million in net sales of the product this year; we successfully launched our new sales force with the goal of growing this trusted brand, which to this day remains the only FDA-approved and clinically proven treatment for these very sick patients with severe C. difficile infection (CDI); and, our work continued in optimizing the manufacturing for our non-toxigenic C. difficile opportunity which we hope to move into human trials later this year."

Continued Milano, "We look forward to a number of significant events throughout 2008, starting in May with the completion of enrollment in our stem cell transplant study of maribavir. In the coming months, we anticipate the publication of the IDSA/SHEA CDI treatment guidelines which highlight the recommendation of Vancocin for treating patients with severe disease based upon compelling clinical trial data that demonstrated the superiority of Vancocin in this patient population."

Net income in the first quarter ended March 31, 2008 was $17.5 million compared to $22.1 million for the same period in 2007. Net income per share for the quarter ended March 31, 2008 was $0.25 per share, basic and $0.22 per share, diluted, compared to a net income of $0.32 per share, basic, and $0.31 per share, diluted, for the same period in 2007. The primary drivers of the change in net income for the first quarter were the effects of decreased operating income discussed above, partially offset by increased interest income and a lower effective tax rate.

Operating Highlights

During the three months ended March 31, 2008, net sales of Vancocin increased 3.9 percent compared to the same period in 2007. The increase resulted from the impact of a price increase in February 2008, partially offset by a decrease in sales volume.

The cost of sales for Vancocin for the three months ended March 31, 2008 decreased $0.3 million for the three months ended March 31, 2007 to $1.9 million from $2.2 million for the same period in 2007 due primarily to the decrease in sales volume.

The total remaining costs and expenses associated with operating income were $29.5 million and $13.9 million, for the first quarter of 2008 and 2007, respectively. These increases are primarily due to research and development costs, increased compensation related to our European operations and Vancocin sales force, medical education activities and marketing costs.

The Company's effective income tax rate was 28.5 percent and 39.4 percent for the quarters ended March 31, 2008 and 2007, respectively. Income tax expense includes federal, state and foreign income tax at statutory rates and the effects of various permanent differences. The decrease in the effective rate for the quarter ended March 31, 2008 as compared to the comparative periods in 2007 is primarily due to our current estimate of the impact of orphan drug credit for maribavir. We currently anticipate an effective tax rate in the range of approximately 27 percent to 31 percent for the year ended December 31, 2008, which includes an estimate related to orphan drug credit based upon estimates of qualified expenses and excludes the impact of discreet items and any potential changes in the valuation allowance. We continue to evaluate our qualified expenses and, to the extent that actual qualified expenses vary significantly from our estimates, our effective tax rate will be impacted.

Regarding additional payments due to Lilly in connection with the Vancocin acquisition, net sales as of March 31, 2008 exceeded the milestone threshold of $45.0 million. As a result, the Company recorded additional purchase price of $2.1 million to intangible assets in March 2008.

Working Capital Highlights

As of March 31, 2008, ViroPharma's working capital was $619.5 million, which represents a $25.1 million increase from December 31, 2007. The three month increase is primarily the result of cash flows.

Looking ahead in 2008

ViroPharma is commenting upon previously announced guidance for the year 2008 as a convenience to investors. The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties. For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2008, ViroPharma expects the following

-- Net product sales are expected to be $210 to $235 million;

-- Research and development (R&D) and selling, general and administrative
(SG&A) expenses, excluding the impact of SFAS 123R, are expected to be
$105 to $115 million.

-- The SFAS 123R impact to the above expenses will be in the range of $9
to $11 million. Including the impact of SFAS 123R, the research and
development (R&D) and sales, general and administrative (SG&A) expenses
are expected to be between $114 and $126 million.

Non-GAAP Disclosures

This press release includes non-GAAP financial information as the Company's projected research and development and marketing, general and administrative expenses has been presented excluding the effect of stock option expense resulting from the application of SFAS 123R. The Company believes that presenting its research and development (R&D) expense and sales, general and administrative (SG&A) expense in this release both with and without the impact of share-based compensation will allow investors to better understand the Company's financial results and how such results compare with the Company's prior results and current guidance.

Conference Call and Webcast

ViroPharma is hosting a live teleconference and webcast with senior management to discuss the financial announcement, guidance, and other business results on April 30, 2008 at 9:00 a.m. Eastern Time. To participate in the conference call, please dial 877-366-0713 (domestic) and 302-607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

Alternatively, the live webcast of the conference call can be accessed via ViroPharma's website at http://www.viropharma.com/.

Windows Media or Real Player will be needed to access the webcast. An audio archive will be available at the same address until May 14, 2008.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in infectious diseases including cytomegalovirus (CMV) and non-toxigenic C. difficile (NTCD). For more information on ViroPharma, visit the Company's website at www.viropharma.com.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward looking statements in this press release include the Company's financial guidance for 2008, and statements regarding ViroPharma's clinical development programs, including our ability to file an initial NDA for Camvia in 2009, commence clinical studies of NTCD in humans during 2008, the timing and content of final IDSA/SHEA CDI treatment guidelines or our ability to execute a future successful launch of Camvia. ViroPharma's 2008 revenue guidance is based upon the Company's plans to remain vigorous in its opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in ViroPharma's Vancocin related submissions or that ViroPharma's efforts to oppose the OGD's March 2006 recommendation to determine bioequivalence to Vancocin through in vitro dissolution testing will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either ViroPharma's citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the OGD in March 2006, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancocin and our financial performance. The company's actual results may vary depending on a variety of factors, including:

-- the development of competitive generic versions of oral Vancocin,
-- approval of products which are currently marketed for other indications
by other companies or new pharmaceuticals and technological advances to
treat the conditions addressed by Vancocin;
-- fluctuations in wholesaler order patterns and inventory levels;
-- manufacturing, supply or distribution interruptions, including but not
limited to our ability to acquire adequate supplies of Vancocin to meet
demand for the product;
-- changes in prescribing or procedural practices of infectious disease,
gastroenterology and internal medicine doctors, including off-label
prescribing of other products;
-- the timing of regulatory submissions and approvals;
-- actions by the FDA, the Internal Revenue Service or other government
regulatory agencies;
-- decreases in the rate of infections for which Vancocin is prescribed;
-- decrease in the sensitivity of the relevant bacteria to Vancocin;
-- changes in terms required by wholesalers, including fee-for-service
contracts;
-- the timing and results of anticipated events in the Company's CMV and
NTCD programs; and
-- the timing and nature of potential business development activities
related to the Company's efforts to expand its current portfolio
through in-licensing or other means of acquiring products in clinical
development or marketed products.

There can be no assurance that FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of the company's product candidates, or that the company will be successful in gaining regulatory approval of any of its product candidates. These factors, and other factors, including, but not limited to those described in ViroPharma's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission during 2008, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements.

VIROPHARMA INCORPORATED
Selected Financial Information

Consolidated Statements of Operations: Three months ended
(in thousands, except per share data) March 31,
----------------------
2008 2007
------- -------
(unaudited)
Revenue:
Net product sales $50,937 $49,029
------- -------
Revenue 50,937 49,029
------- -------

Costs and Expenses:
Cost of sales (excluding amortization
of product rights) 1,918 2,230
Research and development 14,968 5,529
Marketing, general and administrative 12,846 6,973
Intangible amortization 1,688 1,376
------- -------
Total costs and expenses 31,420 16,108
------- -------
Operating income 19,517 32,921

Interest income 6,311 3,580
Interest expense (1,419) (92)
------- -------
Income before income tax expense 24,409 36,409
Income tax expense (benefit) 6,959 14,351
------- -------
Net income $17,450 $22,058
======= =======

Basic net income per share $0.25 $0.32
======= =======
Diluted net income per share $0.22 $0.31
======= =======

Shares used in computing net income per share
Basic 69,926 69,769
======= =======
Diluted 84,272 71,547
======= =======

Consolidated Balance Sheets: March 31, December 31,
------------------------
(in thousands) 2008 2007
-------- ---------
Cash, cash equivalents and short-term
investments $599,005 $584,328
Working capital 619,460 594,403
Total assets 794,112 776,066
Total stockholders' equity 517,430 496,563

First Call Analyst:
FCMN Contact: robert.doody@viropharma.com

Source: ViroPharma Incorporated

CONTACT: Vincent J. Milano, President, Chief Executive Officer,
+1-610-321-6225, or Will Roberts, Vice President, Corporate Communications,
+1-610-321-6288, both of ViroPharma Incorporated

Web site:

http://www.viropharma.com/

-------
Profile: Transplant News

Growing Awareness of PNH Drives Strong Demand for Soliris(R) in U.S. and Europe

First Non-GAAP Profit; Sales Guidance Revised Upward

Pipeline Progress in Neurology and Cancer

First Quarter 2008 Financial Highlights:

- Soliris(R) (eculizumab) net product sales were $45.5 million in Q1 2008, compared to net product sales of $33.9 million in Q4 2007.

- Q1 GAAP net loss was $4.2 million, or $0.11 net loss per share, compared to a GAAP net loss of $12.3 million, or $0.33 net loss per share, in Q4 2007.

- Q1 non-GAAP net income was $1.6 million, or $0.04 net income per share, compared to a non-GAAP net loss of $8.5 million, or $0.23 net loss per share, in Q4 2007.

CHESHIRE, Conn., April 30 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the quarter ended March 31, 2008.

First Quarter 2008 Financial Results:

For the three months ended March 31, 2008, Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") reported total revenues of $45.6 million compared to total revenues of $6.3 million for the same period in 2007. First quarter 2008 revenues were primarily from net product sales of Soliris(R) (eculizumab): $45.5 million, compared to $1.0 million in the first quarter of 2007 and $33.9 million in the fourth quarter of 2007. Soliris, approved by the U.S. Food and Drug Administration (FDA) in March 2007 and the European Commission (EC) in June 2007, is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening blood disease.

The Company reports both GAAP results and non-GAAP results. Non-GAAP results are equal to GAAP results excluding the impact of share-based compensation. The following summary table is provided for investors' convenience. A further reconciliation and explanation of the GAAP to non-GAAP figures appears at the end of this announcement.

(Millions of U.S. dollars, except per-share data)

Quarter Ended March 31,
2008 2007

Net Product Sales $45.5 $1.0
----------------------
Contract Revenues $0.1 $5.3
----------------------
Total Revenues $45.6 $6.3
----------------------

GAAP Net Loss (4.2) (32.7)
Share-Based Compensation 5.9 5.0
----------------------
Non-GAAP Net Income (Loss) $1.6 $(27.7)

GAAP Net Loss Per Share - Diluted $(0.11) $(0.92)
Non-GAAP Net Income (Loss) Per Share - Diluted $0.04 $(0.78)

Shares Used in Determining GAAP Loss Per Share 37,514 35,361

Shares Used in Determining Non-
GAAP Income (Loss) Per Share 39,081 35,361

First Quarter 2008 (Q1 2008) Non-GAAP Financial Results
-------------------------------------------------------

The Company reported non-GAAP net income for Q1 2008 of $1.6 million, or $0.04 per share, compared to a non-GAAP net loss of $27.7 million, or $0.78 per share, in the year-ago quarter, Q1 2007. Alexion incurred a non-GAAP net loss of $8.5 million, or $0.23 per share, in the prior quarter, Q4 2007.

Alexion's non-GAAP operating expenses for Q1 2008 were $39.5 million, compared to $36.1 million for Q1 2007. Non-GAAP research and development ("R&D") expenses for Q1 2008 were $14.0 million, compared to $18.8 million for the year-ago quarter. The lower R&D costs in Q1 2008 were the result of the non-recurrence of expenses associated with drug development, including Soliris registration and the Soliris extension study. Non-GAAP selling, general, and administrative ("SG&A") expenses for Q1 2008 were $25.5 million, compared to $17.2 million for Q1 2007. The increase in non-GAAP SG&A expenses primarily reflected costs associated with the expansion of the Company's commercial operations in the U.S. and Europe.

First Quarter 2008 GAAP Financial Results
-----------------------------------------

On a GAAP basis, operating expenses for Q1 2008 were $45.4 million, compared to $41.1 million for Q1 2007. R&D expenses for Q1 2008 were $15.6 million, compared to $21.2 million for the year-ago quarter. The lower R&D costs in Q1 2008 were the result of the non-recurrence of expenses associated with drug development, including Soliris registration and the Soliris extension study. SG&A expenses were $29.8 million for Q1 2008, compared to $19.8 million for Q1 2007. The increase in GAAP SG&A expenses primarily reflected costs associated with the expansion of the Company's commercial operations in the U.S. and Europe. Operating expenses for Q1 2008 included $5.9 million of share-based compensation expense, compared to $5.0 million in Q1 2007.

The Company recorded investment income of $0.8 million for Q1 2008, compared to $2.8 million in the same period last year. Interest expense in the first quarter was $0.6 million, compared to $0.7 million for the same period last year.

Alexion incurred a GAAP net loss for the first quarter of 2008 of $4.2 million, or $0.11 per share, compared to a GAAP net loss of $32.7 million, or $0.92 per share, for Q1 2007. The GAAP net loss in Q1 2008 was reduced from a GAAP net loss of $12.3 million, or $0.33 per share in the prior quarter, Q4 2007.

Balance Sheet:

As of March 31, 2008, the Company had $107.0 million in cash, cash equivalents, restricted cash, and marketable securities, compared to $106.7 million at December 31, 2007. During the quarter, the Company drew down $18 million from its recently arranged credit facility for working capital purposes.

"Demand for Soliris increased significantly in both the United States and Europe, as we educated more physicians, patients and payors about PNH and the compelling data from Soliris clinical trials," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "Our non-GAAP profit in the first quarter resulted from continued strong momentum in the Soliris launch, combined with the rigorous financial discipline we have applied as our organization has grown. The scientific, commercial and financial success of Alexion makes it possible for us to help more patients with PNH and research promising therapies for other serious and rare diseases."

Research and Development:

Soliris as a Treatment for Patients with PNH
--------------------------------------------

As previously announced, the Company has completed enrolling patients in its AEGIS study, a single registration study to evaluate the safety, efficacy and pharmacology of Soliris as a treatment for Japanese patients with PNH. After the last patient has completed the study's 12-week regimen of Soliris therapy, researchers will collect and analyze data later this year.

Soliris as a Treatment for Patients with Rare and Severe Diseases
-----------------------------------------------------------------

With the FDA approval of Soliris as a treatment for PNH in 2007, Alexion became the first company to discover and develop a terminal complement inhibitor into a viable commercial product. The Company anticipates investigating the use of Soliris as a treatment for patients with other complement-mediated disorders. For example, Alexion has submitted an Investigational New Drug application (IND) to commence a clinical study of Soliris as a treatment for patients with myasthenia gravis, a disabling and sometimes life-threatening neurologic disorder.

Other Studies of Soliris
------------------------

The Company continues to evaluate proposals from researchers with respect to investigator-sponsored trials of Soliris as a treatment for patients with other conditions. The Company is aware that an investigator-sponsored clinical trial evaluating the use of short-term Soliris therapy in a population of kidney transplant patients who are known to have a higher risk of organ rejection is commencing.

Anti-CD200 Monoclonal Antibody for Cancer
-----------------------------------------

Alexion is developing its novel and proprietary anti-CD200 monoclonal antibody, which is designed to enhance the immune response to several types of malignant tumors. The FDA has authorized the Company's IND for the use of this antibody as a therapy for patients with chronic lymphocytic leukemia (CLL). Alexion expects to begin a clinical trial in patients with CLL during 2008.

Q1 2008 Soliris Commercial Update:

In the first quarter, the Company continued to convert clinical trial patients to full commercial status in European countries and also added significant numbers of patients newly identified during the quarter in the U.S., as well as in Europe.

"Our commercial teams remain focused on helping physicians improve the diagnosis and treatment of PNH and helping patients obtain access to Soliris. Overall, the result has been steady growth in new patient starts and high levels of access and compliance with Soliris therapy," said David Keiser, President and Chief Operating Officer of Alexion. "As in the past, we will expand our commercial team selectively when we see an opportunity to further educate physicians and support patients. All of these activities are in line with our objective that every patient who can benefit from Soliris will have access to it."

Financial Guidance:

As a result of the Company's strong sales performance in the first quarter, Alexion is revising its previously announced guidance for worldwide Soliris net product sales upward, from a range of $200 to $215 million to a range of $215 to $225 million for 2008.

Further, the cost of sales, including actual and estimated royalties, is now expected to be improved to a range of 12 percent to 14 percent of net product sales, as compared to the previous estimate of 14 percent to 16 percent.

Prior financial guidance in other expense areas remains unchanged: excluding share-based compensation of $26 to $28 million, R&D expenses in 2008 are anticipated to be in the range of $65 to $75 million and SG&A expenses in the range of $115 to $125 million.

The Company expects to report a non-GAAP profit for the full year 2008.

Conference Call/Web Cast Information
------------------------------------

Alexion will host a conference call/webcast to discuss matters mentioned in this release. The call is scheduled for today, April 30, 2008, at 10:00 a.m., Eastern Time. To participate in this call, dial 719-325-4776 confirmation code 3348104, shortly before 10:00 a.m., Eastern Time. A replay of the call will be available for a limited period following the call, beginning at 1:00 p.m. Eastern Time today. The replay number is 719-457-0820, confirmation code 3348104. The audio webcast can be accessed at http://www.alexionpharma.com/ .

About Soliris
-------------

Soliris is the first product approved for the treatment of patients with PNH in the U.S. and Europe. PNH is a rare, debilitating, and life-threatening blood disorder defined by the destruction of red blood cells, or hemolysis. In patients with PNH, hemolysis can cause life-threatening thromboses, recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria). Soliris, or eculizumab, is the only treatment that blocks this hemolysis.

About Alexion
-------------

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. The Company is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH, and the Company began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharma.com/ .

This press release includes certain non-GAAP financial measures that involve adjustments to GAAP figures. Alexion believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Alexion's past financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing both management and investors with a more complete understanding of underlying operational results and trends. In addition, these non-GAAP financial measures are among the primary indicators Alexion management uses for planning and forecasting purposes and measuring the company's performance. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures. A reconciliation of the non-GAAP to GAAP figures follows this press release.

[ALXN-E]

This news release contains forward-looking statements, including statements related to guidance regarding anticipated financial results for 2008, potential benefits and commercial potential for Soliris, timing and effect of sales of Soliris in the United States and various European markets, status of reimbursement, price approval and funding processes in Europe, progress in developing commercial infrastructure, interest regarding Soliris in the patient, physician and payor communities and expectations about commencement of clinical trials and studies. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials of Soliris are not predictive of safety and efficacy and Soliris is found to be less safe or effective when utilized in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors (including governmental agencies) will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of PNH patients are inaccurate, the risk that ongoing litigation may be resolved adversely, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Annual Report on Form 10-K for the period ended December 31, 2007 and in our other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

(Financial Tables Follow)

ALEXION PHARMACEUTICALS, INC.
Selected Financial Data
(Unaudited)
(Amounts in thousands, except per share amounts)

Consolidated Statements of Operations Data:
Three Months Ended
March 31
--------------------------
2008 2007
------- ------
Revenues:
Net product sales $45,546 $6,317
Contract research revenues 95 -
------- ------
Total revenues 45,641 6,317

Cost of sales 5,464 85

Operating expenses:
Research and development 15,609 21,219
Selling, general and administrative 29,781 19,838
------- ------
Total operating expenses 45,390 41,057
------- ------

Operating loss (5,213) (34,825)
------- ------

Other income (expense):
Investment income 767 2,769
Interest expense (596) (700)
Foreign currency gain(loss) 703 (27)
------- ------
874 2,042
------- ------

Income tax benefit 90 90
------- ------

Net loss $(4,249) $(32,693)
======= ======

Net loss per share - basic and diluted $(0.11) $(0.92)
======= ======

Shares used in computing basic and
diluted net loss per common share 37,514 35,361
======= ======

Consolidated Balance Sheet Data: As of
---------------------------
March 31, December 31,
2008 2007
-------- -----------
Cash, cash equivalents and
marketable securities (a) $106,964 $106,712
Total assets 363,994 334,357
Total stockholders' equity 108,039 101,556

(a) Amount includes restricted cash of $417 and $958
at March 31, 2008 and December 31, 2007, respectively.

ALEXION PHARMACEUTICALS, INC.
Selected Financial Data
(Unaudited)
(Amounts in thousands, except per share amounts)

Non-GAAP financial information is adjusted to exclude the impact of share-based compensation. The following table represents a reconciliation of GAAP to non-GAAP financial information for the three months ended March 31, 2008 and 2007, as well as the three months ended December 31, 2007:

Non-GAAP
Share-Based Excluding
Reported Compensa- Share-
GAAP tion Based
Amounts Adjustment Compensation
-------- ---------- ------------

Three Months Ended March 31, 2008
Research and development $15,609 $(1,625) $13,984
Selling, general and administrative 29,781 (4,260) 25,521
Operating expenses 45,390 (5,885) 39,505
Operating income (loss) (5,213) 5,885 672
Net income (loss) (4,249) 5,885 1,636

Basic and diluted net income (loss)
per share $(0.11) $0.16 $0.04

Three Months Ended March 31, 2007
Research and development $21,219 $(2,385) $18,834
Selling, general and administrative 19,838 (2,596) 17,242
Operating expenses 41,057 (4,981) 36,076
Operating loss (34,825) 4,981 (29,844)
Net loss (32,693) 4,981 (27,712)

Basic and diluted net loss per share $(0.92) $0.14 $(0.78)

Three Months Ended December 31, 2007
Research and development $15,643 $(989) $14,654
Selling, general and administrative 28,570 (2,799) 25,771
Operating expenses 44,213 (3,788) 40,425
Operating loss (13,746) 3,788 (9,958)
Net loss (12,330) 3,788 (8,542)

Basic and diluted net loss per share $(0.33) $0.10 $(0.23)

First Call Analyst:
FCMN Contact: etaylor@rxir.com

Source: Alexion Pharmaceuticals, Inc.

CONTACT: Irving Adler, Sr. Director, Corporate Communications, of
Alexion Pharmaceuticals, Inc., +1-203-271-8210; or Media, Kristie Kuhl, of
Makovsky & Company, +1-212-508-9642; or Investors, Rhonda Chiger, of Rx
Communications, +1-917-322-2569

-------
Profile: Transplant News